Home > Oncology > ESMO 2021 > Gastrointestinal Cancer > ctDNA highly predictive in HER2-positive, advanced gastric or gastro-oesophageal junction cancer

ctDNA highly predictive in HER2-positive, advanced gastric or gastro-oesophageal junction cancer

Presented By
Dr Alexander Stein, University Cancer Center Hamburg, Germany
Conference
ESMO 2021
Trial
Phase 2, INTEGA
First-line trastuzumab/nivolumab/FOLFOX6 outperforms trastuzumab/nivolumab/ipilimumab in HER2-positive, advanced gastric or gastro-oesophageal cancer, first results from INTEGA showed. In addition, circulating tumour (ct)DNA appeared to be highly predictive, independent of treatment arm. Previously, results from the ToGA trial showed survival benefit for first-line trastuzumab in combination with chemotherapy in patients with HER2-positive, advanced gastric or gastro-oesophageal junction cancer [1]. In addition, immunotherapy has been shown to be superior to chemotherapy as a first-line treatment in patients with gastro-oesophageal adenocarcinoma [2]. The phase 2 INTEGA trial (NCT03409848) compared different immunotherapy regimens in first-line treatment of HER2-positive gastro-oesophageal adenocarcinoma. A total of 88...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on